Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.755 USD | +1.21% | +6.33% | +75.91% |
May. 14 | Acrivon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 442K | Capitalization | 267M |
---|---|---|---|---|---|
Net income 2024 * | -81M | Net income 2025 * | -102M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 605 x |
P/E ratio 2024 * |
-3.09
x | P/E ratio 2025 * |
-3
x | Employees | 60 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.58% |
1 day | +1.21% | ||
1 week | +6.33% | ||
Current month | -4.79% | ||
1 month | -8.61% | ||
3 months | +119.67% | ||
6 months | +94.93% | ||
Current year | +75.91% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 18-03-31 | |
Kristina Masson
FOU | Founder | 44 | 18-02-28 |
Director of Finance/CFO | 53 | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | Feb. 07 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 20-09-30 |
Chief Executive Officer | 62 | 18-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.64% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 8.655 | +0.06% | 4 450 |
24-05-15 | 8.65 | +3.47% | 38,547 |
24-05-14 | 8.36 | -1.42% | 84,937 |
24-05-13 | 8.48 | -3.31% | 59,770 |
24-05-10 | 8.77 | +7.74% | 100,179 |
Delayed Quote Nasdaq, May 16, 2024 at 10:00 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.91% | 267M | |
+31.14% | 49.46B | |
+1.13% | 42.58B | |
+49.11% | 42.49B | |
-5.26% | 29.09B | |
+12.67% | 26.61B | |
-23.78% | 18.64B | |
+7.40% | 13.16B | |
+31.63% | 12.55B | |
+23.06% | 12.1B |
- Stock Market
- Equities
- ACRV Stock